References
- EttingerDSWoodDEAkerleyWNational Comprehensive Cancer NetworkNon-small cell lung cancer, version 6. 2015J Natl Compr Canc Netw201513551552425964637
- SolomonBJMokTKimDWPROFILE 1014 InvestigatorsFirst-line crizotinib versus chemotherapy in ALK-positive lung cancerN Engl J Med2014371232167217725470694
- ShawATKimDWNakagawaKCrizotinib versus chemotherapy in advanced ALK-positive lung cancerN Engl J Med2013368252385239423724913
- MatikasAKentepozidisNGeorgouliasVKotsakisAManagement of resistance to crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancerClin Lung Cancer201617647448227341790
- YuHAArcilaMERekhtmanNAnalysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancersClin Cancer Res20131982240224723470965
- ChaYJChoBCKimHRLeeHJShimHSA case of ALK-rearranged adenocarcinoma with small cell carcinoma-like transformation and resistance to crizotinibJ Thorac Oncol2015115e55e5826752677
- TakegawaNHayashiHIizukaNTransformation of ALK rearrangement-positive adenocarcinoma to small cell lung cancer in association with acquired resistance to alectinibAnn Oncol20162752532
- FujitaSMasagoKKatakamiNYatabeYTransformation to SCLC after treatment with the ALK inhibitor AlectinibJ Thorac Oncol2016116e67e7226751586
- MiyamotoSIkushimaSOnoRTransformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinibJpn J Clin Oncol201646217017326613679
- CaumontCVeillonRGrosALaharanneEBégueretHMerlioJPNeuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinomaLung Cancer201692151826775590
- LevacqDD’HaeneNde WindRRemmelinkMBerghmansTHistological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: a new mechanism of resistance to ALK inhibitorsLung Cancer2016102384127987586
- OuSILeeTKYoungLDual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?Lung Cancer201710611011428285684
- CamidgeDRDoebeleRCTreating ALK-positive lung cancer-early success and future challengesNat Rev Clin Oncol20129526827722473102
- IsozakiHTakigawaNKiuraKMechanisms of acquired resistance to ALK inhibitors and the rationale for treating ALK-positive lung cancerCancers (Basel)20157276378325941796
- NorkowskiEGhignaMRLacroixLSmall-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathologyJ Thorac Oncol20138101265127124457237
- OserMGNiederstMJSequistLVEngelmanJATransformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of originLancet Oncol2015164e165e17225846096
- KalemkerianGPAkerleyWBognerPSmall cell lung cancerJ Natl Compr Canc Netw2013111789823307984
- SequistLVWaltmanBADias-SantagataDGenotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsSci Transl Med201137575ra26
- KikuchiHSakakibara-KonishiJFurutaMExpression of Notch1 and Numb in small cell lung cancerOncotarget201786103481035828060745